T. Rowe Price Investment Management

T. Rowe Price Investment Management Portfolio holdings

AUM $158B
1-Year Est. Return 18.51%
 

T. Rowe Price Investment Management, Inc. (TRPIM), a division of T. Rowe Price Group established in August 2022 and headquartered in Baltimore, Maryland, is an active investment manager overseeing hundreds of billions in assets, focusing on equity and fixed-income strategies for institutional clients and sub-advisory mandates. Spun off from the parent company founded in 1937 by Thomas Rowe Price, Jr., TRPIM operates as a distinct entity with around 900 employees, emphasizing a research-driven, long-term approach rooted in fundamental analysis and disciplined risk management. Managing portfolios like large-cap growth and international equity funds, it complements T. Rowe Price’s broader offerings while targeting sophisticated investors such as pension funds and endowments with tailored, high-conviction solutions. Under the leadership of president Rob Sharps, TRPIM upholds the firm’s legacy of integrity and client focus, adapting its founder’s value-oriented philosophy to modern institutional needs.

This Fund
S&P 500
This Quarter Est. Return
1 Year Est. Return
+18.51%
3 Year Est. Return
5 Year Est. Return
10 Year Est. Return
AUM
$158B
AUM Growth
-$5.16B
Cap. Flow
Cap. Flow %
Top 10 Hldgs %
Holding
963
New
Increased
Reduced
Closed

Top Buys

1 +$1.41B
2 +$1.23B
3 +$1.06B
4
AJG icon
Arthur J. Gallagher & Co
AJG
+$861M
5
AVGO icon
Broadcom
AVGO
+$822M

Top Sells

1 +$1.18B
2 +$1.14B
3 +$1.05B
4
ROP icon
Roper Technologies
ROP
+$918M
5
DTE icon
DTE Energy
DTE
+$834M

Sector Composition

1 Technology 25.49%
2 Healthcare 20.04%
3 Consumer Discretionary 12.91%
4 Financials 12.54%
5 Industrials 9.21%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
IQV icon
651
IQVIA
IQV
$27B
$582K ﹤0.01%
2,578
-1,696
CORT icon
652
Corcept Therapeutics
CORT
$4.84B
$541K ﹤0.01%
15,530
-8,909
AMAT icon
653
Applied Materials
AMAT
$321B
$412K ﹤0.01%
1,602
-2,359
ADI icon
654
Analog Devices
ADI
$197B
$349K ﹤0.01%
1,286
-2,951
CVS icon
655
CVS Health
CVS
$101B
$241K ﹤0.01%
3,034
-376
HUM icon
656
Humana
HUM
$26.1B
$198K ﹤0.01%
771
-60,659
DXCM icon
657
DexCom
DXCM
$24.2B
$179K ﹤0.01%
2,687
+538
EW icon
658
Edwards Lifesciences
EW
$46B
$165K ﹤0.01%
1,929
-577
SNY icon
659
Sanofi
SNY
$114B
$151K ﹤0.01%
3,108
+619
PODD icon
660
Insulet
PODD
$13.3B
$97K ﹤0.01%
338
+248
INCY icon
661
Incyte
INCY
$19B
$65K ﹤0.01%
+652
AZN icon
662
AstraZeneca
AZN
$298B
$64K ﹤0.01%
694
-447
ABVX
663
Abivax
ABVX
$8.96B
$61K ﹤0.01%
+452
ALKS icon
664
Alkermes
ALKS
$5.64B
$59K ﹤0.01%
+2,099
AMLX icon
665
Amylyx Pharmaceuticals
AMLX
$1.94B
$55K ﹤0.01%
4,517
-1,193,547
ADPT icon
666
Adaptive Biotechnologies
ADPT
$2.19B
$51K ﹤0.01%
+3,128
APLS icon
667
Apellis Pharmaceuticals
APLS
$5.23B
$50K ﹤0.01%
1,974
-46,782
MLTX icon
668
MoonLake Immunotherapeutics
MLTX
$1.24B
$47K ﹤0.01%
+3,557
ROIV icon
669
Roivant Sciences
ROIV
$20.1B
$45K ﹤0.01%
2,048
-581
LLYVA icon
670
Liberty Live Group Series A
LLYVA
$8.39B
$43K ﹤0.01%
521
+15
SOLV icon
671
Solventum
SOLV
$12B
$43K ﹤0.01%
538
+504
NVCR icon
672
NovoCure
NVCR
$1.46B
$41K ﹤0.01%
3,143
-942,283
NVO icon
673
Novo Nordisk
NVO
$171B
$41K ﹤0.01%
+802
CNTA
674
Centessa Pharmaceuticals
CNTA
$6.11B
$39K ﹤0.01%
1,536
+1,516
RCUS icon
675
Arcus Biosciences
RCUS
$3.07B
$39K ﹤0.01%
+1,625